RNA splicing as a therapeutic target in myelodysplastic syndromes DOI Creative Commons

C.-C. Tseng,

Esther A. Obeng

Seminars in Hematology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological disorders and are more commonly found in people over the age 60. MDS patients exhibit peripheral blood cytopenias carry an increased risk disease progression to acute myeloid leukemia (AML). Splicing factor mutations (including genes SF3B1, SRSF2, U2AF1, ZRSR2) early events identified than 50% cases. These cause aberrant pre-mRNA splicing impact pathophysiology. Emerging evidence shows that factor-mutant cells sensitive perturbations targeting spliceosome, aberrantly spliced and/or their regulated molecular pathways. This review summarizes current therapeutic strategies ongoing efforts for treatment MDS.

Language: Английский

Corneal endothelial dysfunction treatments: Recent advances in non-invasive treatment strategies DOI Creative Commons
Nataliia Gnyliukh, Rabah Boukherroub, Sabine Szunerits

et al.

Nano Today, Journal Year: 2025, Volume and Issue: 63, P. 102740 - 102740

Published: April 4, 2025

Language: Английский

Citations

0
Creation of biomimetic polyethylenimine quantum dots nanocomposites for traceable and targeted DNA delivery DOI
Mingjie Wang,

Guowei Qi,

Jiayu He

et al.

Journal of Molecular Liquids, Journal Year: 2024, Volume and Issue: 408, P. 125320 - 125320

Published: June 20, 2024

Language: Английский

Citations

3
RNA splicing as a therapeutic target in myelodysplastic syndromes DOI Creative Commons

C.-C. Tseng,

Esther A. Obeng

Seminars in Hematology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological disorders and are more commonly found in people over the age 60. MDS patients exhibit peripheral blood cytopenias carry an increased risk disease progression to acute myeloid leukemia (AML). Splicing factor mutations (including genes SF3B1, SRSF2, U2AF1, ZRSR2) early events identified than 50% cases. These cause aberrant pre-mRNA splicing impact pathophysiology. Emerging evidence shows that factor-mutant cells sensitive perturbations targeting spliceosome, aberrantly spliced and/or their regulated molecular pathways. This review summarizes current therapeutic strategies ongoing efforts for treatment MDS.

Language: Английский

Citations

1